PE20040290A1 - Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp - Google Patents

Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp

Info

Publication number
PE20040290A1
PE20040290A1 PE2003000261A PE2003000261A PE20040290A1 PE 20040290 A1 PE20040290 A1 PE 20040290A1 PE 2003000261 A PE2003000261 A PE 2003000261A PE 2003000261 A PE2003000261 A PE 2003000261A PE 20040290 A1 PE20040290 A1 PE 20040290A1
Authority
PE
Peru
Prior art keywords
alkyl
substituted
phenyl
aminoalkyl
cgrp
Prior art date
Application number
PE2003000261A
Other languages
English (en)
Inventor
Kirsten Arndt
Eckhart Bauer
Alexander Dreyer
Muller Stephan Georg Georg
Marcus Schindler
Rudolf Hurnaus
Phillipp Lustenberger
Klaus Rudolf
Kai Gerlach
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20040290A1 publication Critical patent/PE20040290A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

SE REFIERE A COMPUESTOS SUSTITUIDOS DE PIPERIDINAS DE FORMULA (I) DONDE R ES AZA-, DIAZA-, TRIAZA-, OXAZA-,TIAZA-, TIADIAZA- O S, S-DIOXIDO-TIADIAZA HETEROCICLO DE 5 A 7 MIEMBROS, CON 1 O 2 CARBONILOS UNIDOS AL MENOS A UN N Y PUEDEN ESTAR SUSTITUIDOS 1 O 2 CARBONOS POR ALQUILO, FENILO,NAFTILO, ENTRE OTROS; X ES O, EN TANTO Z SEA -NR1-, =N-CN O =N-SO2-R6, DONDE R6 ES UN ALQUILO C1-C4 O FENILO SUSTITUIDO; Z ES -CH2- QUE PUEDE ESTAR SUSTITUIDO POR F, ALQUILO C1-C3 O -NR1-; A ES C SUSTITUIDO CON H O ALQUILO C1-C3; n ES 1 O 2; R2 ES UN FENILO TRI SUSTITUIDO POR Ra, Rb, Rc LOS QUE SON H, HALOGENO, ALQUILO, HIDROXI, ALCOXI, TRIFLUOROMETILO, ENTRE OTROS; R3 Y R4 PUEDEN SER H, ALQUILO C1-C4, AMINOALQUILO C1-C3, ALQUIL C1-C3-AMINOALQUILO C1-C3 O DI-(ALQUIL C1-C3)-AMINOALQUILO C1-C3, FENILO O NAFTILO QUE PUEDEN ESTAR SUSTITUIDO POR Rd, QUE ES UN HALOGENO, ALQUILO C1-C3 ENTRE OTROS; R5 ES -(CH2)m-Re, DONDE m ES 0 Y Re ES H, FENILO O NAFTILO SUSTITUIDO, O m es 1 a 5 Y Re ES H, AMINOMETILENO, ENTRE OTROS.SON COMPUESTOS PREFERIDOS: AMIDA {(R)-2-(4-AMINO-3,5-DIBROMO-FENIL)-1-[1-(3-DIMETILAMINO-PROPIL)1H-BENCENIMIDAZOL-2-IL]-ETILICA} DEL ACIDO 4-(2-OXO-1,2,4,5-TETRAHIDRO-1,3-BENCENDIAZEPIN-3-IL)-PIPERIDIN-1-CARBOXILICO.LOS COMPUESTOS SON ANTAGONISTAS DE CGRP, Y PUEDEN SER UTILES EN EL TRATAMIENTO DE DIABETES MELLITUS NO DEPENDIENTE DE INSULINA,ENFERMEDADES CARDIOVASCULARES,INTOLERANCIA A LA MORFINA,ENFERMEDADES DE LA PIEL,ENFERMEDADES INFLAMATORIAS,ENTRE OTRAS.
PE2003000261A 2002-03-14 2003-03-14 Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp PE20040290A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10211770A DE10211770A1 (de) 2002-03-14 2002-03-14 Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
PE20040290A1 true PE20040290A1 (es) 2004-07-01

Family

ID=27797848

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000261A PE20040290A1 (es) 2002-03-14 2003-03-14 Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp

Country Status (12)

Country Link
EP (1) EP1487821B1 (es)
JP (1) JP4309288B2 (es)
AR (1) AR039569A1 (es)
AT (1) ATE357440T1 (es)
AU (1) AU2003212323A1 (es)
CA (1) CA2476031A1 (es)
DE (2) DE10211770A1 (es)
ES (1) ES2283754T3 (es)
PE (1) PE20040290A1 (es)
TW (1) TW200404066A (es)
UY (1) UY27722A1 (es)
WO (1) WO2003076432A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
WO2005004869A1 (en) * 2003-07-07 2005-01-20 Boehringer Ingelheim International Gmbh Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
JP2007524568A (ja) 2003-12-05 2007-08-30 ブリストル−マイヤーズ　スクイブ　カンパニー カルシトニン遺伝子関連ペプチドレセプターアンタゴニスト
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7547694B2 (en) 2004-04-15 2009-06-16 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018796A1 (de) * 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
AU2005258135B2 (en) 2004-06-18 2011-09-22 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
EP1791843B1 (en) * 2004-09-08 2012-08-29 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam cgrp receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
NZ577727A (en) 2007-01-05 2012-03-30 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
EP2086958B1 (en) * 2007-08-31 2015-01-14 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
CN105061251B (zh) * 2008-08-01 2019-04-19 三井化学Agro株式会社 苯胺衍生物
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
US10173999B2 (en) * 2015-02-27 2019-01-08 Toray Industries, Inc. Cyclic amine derivative and pharmaceutical use thereof
JP6642422B2 (ja) * 2015-03-24 2020-02-05 東レ株式会社 環状アミン誘導体及びその医薬用途
WO2016152952A1 (ja) * 2015-03-24 2016-09-29 東レ株式会社 環状アミン誘導体及びその医薬用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952146A1 (de) * 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19963868A1 (de) * 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
ATE357440T1 (de) 2007-04-15
ES2283754T3 (es) 2007-11-01
DE10211770A1 (de) 2003-10-02
AU2003212323A1 (en) 2003-09-22
EP1487821B1 (de) 2007-03-21
DE50306850D1 (de) 2007-05-03
JP4309288B2 (ja) 2009-08-05
AR039569A1 (es) 2005-02-23
JP2005527519A (ja) 2005-09-15
UY27722A1 (es) 2003-10-31
TW200404066A (en) 2004-03-16
EP1487821A1 (de) 2004-12-22
WO2003076432A1 (de) 2003-09-18
CA2476031A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
PE20040290A1 (es) Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
AR069849A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20080251A1 (es) Usos de inhibidores de dpp iv
PE20060336A1 (es) Compuestos derivados de 1-amino-ftalazina como moduladores de mch1
PE20040458A1 (es) Piridinas sustituidas con actividad anti-angiogenica
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20081846A1 (es) Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico
PE20080543A1 (es) Nuevos derivados de fenilo, piridina y quinolina
ECSP066414A (es) Derivados de malonamida que bloquean la actividad de gama-secretasa
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
UY28090A1 (es) Derivados de acido mandelico
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
NO20072389L (no) Substituerte benzokinolizinderivater
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
PE20090592A1 (es) Nuevos derivados de piperazina-amida
RU2008144962A (ru) Замещенные имидазол-4-карбоксамиды в качестве модуляторов рецепторов холецистокина-1
PE20081496A1 (es) Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1

Legal Events

Date Code Title Description
FD Application declared void or lapsed